ACTRN12612000632897已完成3 期
A prospective, randomised, double-blind, active control, parallel assessment, intention to treat, safety and efficacy study comparing light and deep general anesthesia monitored with Bispectral Index (BIS) to investigate whether depth of anesthesia alters peri-operative outcomes in patients having major surgery
Assoc Professor Dr Timothy Short0 个研究点目标入组 6,649 人开始时间: 2012年6月13日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6,649
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 60 Years 至 o limit（—）
- 性别
- All
入选标准
- •Age equal to/greater than 60 years, ASA grade 3 or 4, surgery expected to last >2 hours, post-operative hospital stay expected to be 2 or more nights, general anaesthesia with or without major regional block.
排除标准
- •Unable to monitor BIS (eg cranial or intracranial surgery), not expected to survive one year, unable to consent, not expected to be contactable in one year, surgery with ‘wake-up’ test.
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil MMF in inducing response and maintaining remission in subjects with lupus nephritisupus nephritis LNMedDRA version: 9.1Level: LLTClassification code 10025140Term: Lupus nephritisEUCTR2004-004917-41-ITASPREVA PHARMACEUTICALS CORPORATIO358
进行中（未招募）
不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis. - Aspreva Lupus Management Study (ALMS)EUCTR2004-004917-41-PTAspreva Pharmaceuticals Corporation as part of the Roche-Aspreva Collaboration Agreement358
进行中（未招募）
不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis. - Aspreva Lupus Management Study (ALMS)upus NephritisMedDRA version: 4.1Level: LowClassification code 10025140EUCTR2004-004917-41-HUAspreva Pharmaceuticals Corporation as part of the Roche-Aspreva Collaboration Agreement358
进行中（未招募）
不适用
linagliptin in combination with metformin in treatment naive patients with type 2 diabetes mellitus and insufficient glycaemic controlType 2 diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002276-16-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,360
进行中（未招募）
1 期
linagliptin in combination with metformin in treatment naive patients with type 2 diabetes mellitus and insufficient glycaemic control.Type 2 diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002276-16-ESBoehringer Ingelheim España, S.A.1,360